Current commercial dPCR platforms: technology and market review

Crit Rev Biotechnol. 2023 May;43(3):433-464. doi: 10.1080/07388551.2022.2037503. Epub 2022 Mar 15.

Abstract

Digital polymerase chain reaction (dPCR) technology has provided a new technique for molecular diagnostics, with superior advantages, such as higher sensitivity, precision, and specificity over quantitative real-time PCRs (qPCR). Eight companies have offered commercial dPCR instruments: Fluidigm Corporation, Bio-Rad, RainDance Technologies, Life Technologies, Qiagen, JN MedSys Clarity, Optolane, and Stilla Technologies Naica. This paper discusses the working principle of each offered dPCR device and compares the associated: technical aspects, usability, costs, and current applications of each dPCR device. Lastly, up-and-coming dPCR technologies are also presented, as anticipation of how the dPCR device landscape may likely morph in the next few years.

Keywords: Digital PCR; QX100; QX200; QuantStudio; equipment; instrument; polymerase chain reaction; real-time PCR.

Publication types

  • Review

MeSH terms

  • Biotechnology
  • Commerce
  • Real-Time Polymerase Chain Reaction* / methods